# New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Canonical URL: https://biopharmsignal.com/news/ARQT/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology
Ticker: ARQT
Company: Arcutis Biotherapeutics
Source: Arcutis Biotherapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.arcutis.com
## Summary

Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert clinicians Genital

## Article Body
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert clinicians Genital
## Recent Company News
- 2026-07-02 20:00 EST — [Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-6524924c) — Source: Arcutis Biotherapeutics
- 2026-06-30 13:16 EST — [Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications](https://biopharmsignal.com/news/ARQT/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-indiv-1503fca8) — Source: Arcutis Biotherapeutics
- 2026-06-29 23:07 EST — [FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2](https://biopharmsignal.com/news/ARQT/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-ps-597a9084) — Source: Arcutis Biotherapeutics
- 2026-06-25 13:46 EST — [New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology](https://biopharmsignal.com/news/ARQT/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology) — Source: Arcutis Biotherapeutics
- 2026-06-25 13:46 EST — [Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Arcutis Biotherapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)